Phase 2 N=17 Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis
Cardiac Sarcoidosis
Primary: Change in Inflammation Marker — -43; 7 mg/L
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=15 d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis
Cardiac Sarcoidosis
Primary: 68Ga-DOTATATE Uptake With Cardia Sarcoidosis (CS)
N/A N=17 Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis
Sarcoidosis
Primary: Number of Participants Characterized by Abnormal or Negative Uptake — 4; 3; 6 Participants
Phase 1 N=15 Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis
Pulmonary Sarcoidosis · Lung Function
Primary: Change in Absolute FVC From Baseline to Post Completion of 8 Weeks of Antibiotic Therapy. — 2.61 liters
N/A N=119 Early Identification of Myocardial Impairment in PBC
Primary Biliary Cholangitis · Cardiovascular Abnormalities
Primary: The Incidence of Cardiac Events — 0; 0; 0; 0 Participants — p=0.001
N/A N=151 Systemic Lupus Erythematous and Heart Conduction Disorders
Lupus Erythematosus, Systemic · Atrioventricular Block · Sudden Death
Primary: Presence of Conduction Disorders in Patients With SLE Regarding to Its Serologic Profile — 89.22; 91.41; 145.68; 146.72 msec
Phase 2 N=55 Atorvastatin to Treat Pulmonary Sarcoidosis
Sarcoidosis, Pulmonary
Primary: The Steroid Sparing Period — 301; 257 days
Phase 2 N=40 Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis
Pulmonary Sarcoidosis
Primary: Change Between Baseline and Week 24 in Pulmonary Function as Measured by Spirometry — -1.90; 0.52 Percent Predicted Forced Vital Capacity
N/A N=33 Novel Cardiac Magnetic Resonance Imaging to Define a Unique Restrictive Cardiomyopathy in Sickle Cell Disease
Sickle Cell Disease
Primary: Frequency of the Diffuse Myocardial Fibrosis Phenotype — 5; 10; 10; 1 Participants
Phase 4 N=14 Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction
Heart Transplant · Acute Graft Rejection · Chronic Graft Rejection
Primary: Myocardial Perfusion Reserve — 1.52; 1.94 arbitrary units
Phase 2 N=29 Trial of Antimycobacterial Therapy in Sarcoidosis
Sarcoidosis
Primary: Change in Lesion Size at the Completion of Antibiotic Therapy, Measured on a Continuous Scale; Change Will be Determined by Change in Diameter of the Lesions — -8.4…
Phase 2 N=50 Nicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot Study
Sarcoidosis
Primary: Forced Vital Capacity (FVC) — 0.07; -0.07 liters
Phase 4 N=4 Treatment of CNS Sarcoidosis With H.P. Acthar Gel
CNS Sarcoidosis
Primary: Karnofsky Performance Status (KPS) Score — 76.67; 76.67 score on a scale — p=1.0
Phase 4 N=53 Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy
Myocardial Fibrosis · Hypertrophic Cardiomyopathy
Primary: Absolute Change in Serum Markers of Collagen Turnover (Micrograms/L) Over a One-year Follow-up Period in the Spironolactone Group Compared to Placebo. — 2.1; 2.1; 0.7…
Phase 3 N=12 Tadalafil for Sarcoidosis Associated Pulmonary Hypertension
Pulmonary Hypertension
Primary: 6 Minute Walk Distance — 419.1; 418.1; 436.5; 377.1 meters — p=0.68
N/A N=50 Cardiac Amyloidosis Discovery Trial
Cardiac Amyloidosis
Primary: Rate of Cardiac Amyloidosis Diagnosis — 24 Participants
Phase 2 N=97 Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis
Sarcoidosis; Antimycobacterial Therapy
Primary: Change in Percent Predicted Absolute Forced Vital Capacity (FVC) in Participants With Pulmonary Sarcoidosis, Comparing Baseline With Performance After Completion of 16…
Phase 2 N=62 Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis
Pulmonary Sarcoidosis
Primary: Change in Percent Predicted FVC From Baseline to 16 Weeks of Treatment — -0.48; 1.02 Percent predicted — p=0.1804
N/A N=9 Ocular Sarcoidosis Open Label Trial of ACTHAR Gel
Ocular Sarcoidosis · Panuveitis · Anterior Uveitis
Primary: Percentage of Patients With Clinically Significant Improvement in Visual Acuity — 3 Participants
Phase 2 N=15 Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis
Sarcoidosis
Primary: Number of Participants Without Sarcoidosis Flare (Flare-Free Survival) — 2; 7 Participants
Phase 2 N=173 A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis
Sarcoidosis
Primary: Change From Baseline in Percent-predicted Forced Vital Capacity (FVC) at Week 16 — 2.02; 1.15; -0.15 percent of predicted FVC — p=0.543
N/A N=646 Screening for Cardiac Amyloidosis With Nuclear Imaging for Minority Populations
Amyloid Cardiomyopathy, Transthyretin-Related
Primary: Prevalence of Transthyretin Cardiac Amyloidosis (ATTR-CA) in Cohort of Caribbean Hispanics and Blacks With Heart Failure (HF) — 7.8; 0 percentage of participants
N/A N=17 The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis
Pulmonary Sarcoidosis
Primary: Bronchoalveolar Lavage (BAL) and Peripheral Blood Mononuclear Cells (PBMC) TNF-α Levels — 40767; 39938; 45176; 25671 pg/ml
N/A N=24 Characterizing Chemo-Radiotherapy Treatment-Related Cardiac Changes
Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8 · Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8 · Clinical Stage I Esophageal Adenocarcinoma AJCC v8
Primary: Proportion of Participants With a Cardiac Event at 12 Months — 0.6818 proportion of participants
N/A N=42 Eplerenone for Subclinical Cardiomyopathy in Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy
Primary: 12-month Change in Myocardial Strain — 2.2; 1.0 percent change in heart dimension
N/A N=1 Stereotactic Ablative Radiotherapy for Refractory Ventricular Tachycardia
Refractory Ventricular Tachycardia
Primary: ICD (Implantable Cardioverter Defibrillator) Shock Free Survival — 1 Participants
Phase 1 N=5 Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis
Sarcoidosis, Pulmonary · Sarcoidosis Lung · Sarcoidosis
Primary: Number of Participants With 50% Reduction in Corticosteroid Requirement — 3 Participants
Phase 4 N=23 Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography
Cardiac Amyloidosis
Primary: Mean Left Ventricular Myocardial F-18 Florbetapir SUVmean — 3.2; 1.7; 5.0 ratio
N/A N=24 Long-term Monitoring of Patients With Cardiac Amyloidosis With Implantable Event Monitors
TTR Cardiac Amyloidosis
Primary: Sudden Death — 0 Participants
Phase 4 N=55 Acthar Gel in Participants With Pulmonary Sarcoidosis
Sarcoidosis, Pulmonary
Primary: DBT: Number of Participants in Each Category of Assessment Based on Forced Vital Capacity (FVC), a Pulmonary Function Test Parameter at Week 24 — 10; 7; 12; 12…